Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2016

01-06-2016 | Hepatobiliary Tumors

CD133 Expression at the Metastatic Site Predicts Patients’ Outcome in Colorectal Cancer with Synchronous Liver Metastasis

Authors: Junko Kishikawa, MD, Shinsuke Kazama, MD, PhD, Koji Oba, PhD, Kiyoshi Hasegawa, MD, PhD, Hiroyuki Anzai, MD, Yuzo Harada, MD, Hiroyuki Abe, MD, PhD, Keisuke Matsusaka, MD, PhD, Kumiko Hongo, MD, PhD, Masaru Oba, MD, PhD, Koji Yasuda, MD, PhD, Kensuke Otani, MD, PhD, Takeshi Nishikawa, MD, PhD, Toshiaki Tanaka, MD, PhD, Junichiro Tanaka, MD, PhD, Tomomichi Kiyomatsu, MD, PhD, Keisuke Hata, MD, PhD, Kazushige Kawai, MD, PhD, Hiroaki Nozawa, MD, PhD, Hironori Yamaguchi, MD, PhD, Soichiro Ishihara, MD, PhD, Eiji Sunami, MD, PhD, Tetsuo Ushiku, MD, PhD, Joji Kitayama, MD, PhD, Masashi Fukayama, MD, PhD, Norihiro Kokudo, MD, PhD, Toshiaki Watanabe, MD, PhD

Published in: Annals of Surgical Oncology | Issue 6/2016

Login to get access

Abstract

Background

CD133 is a transmembrane protein that is proposed to be a stem cell marker of colorectal cancer (CRC); however, the correlation between CD133 expression and survival of CRC patients with liver metastasis has not been fully examined.

Methods

CD133 expression was evaluated immunohistochemically, both in primary tumors and synchronous liver metastases of 88 consecutive CRC patients, as well as recurrent lesions in the remnant liver of 27 of these 88 patients. The relationship between CD133 expression and clinicopathological characteristics, recurrence-free survival, and overall survival (OS) was analyzed.

Results

CD133 expression in liver metastases (mCD133) was detected in 50 of 88 patients (56.8 %), and had significant correlation with CD133 expression in primary lesions (pCD133) (p < 0.001). CD133 expression in liver recurrent lesions (recCD133) also had a significant correlation with mCD133 (p < 0.001). mCD133+ patients had significantly longer disease-free survival (p = 0.043) and OS (p = 0.014) than mCD133− patients. In addition, mCD133+ patients had a significantly lower rate of extrahepatic recurrence (p < 0.001).

Conclusions

Patients without CD133 expression in liver metastasis had significantly shorter survival, perhaps because mCD133− patients had a significantly higher rate of extrahepatic recurrence.
Appendix
Available only for authorised users
Literature
1.
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.CrossRefPubMed
2.
Kodeda K, Nathanaelsson L, Jung B, et al. Population-based data from the Swedish Colon Cancer Registry. Br J Surg. 2013;100:1100–7.CrossRefPubMed
3.
Leporrier J, Maurel J, Chiche L, et al. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93:465–74.CrossRefPubMed
4.
Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57 (discussion 657–648).CrossRefPubMedPubMedCentral
5.
Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.CrossRefPubMed
6.
Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.CrossRefPubMed
7.
Beppu T, Miyamoto Y, Sakamoto Y, et al. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival. Ann Surg Oncol. 2014;21 Suppl 3:S405–3.CrossRefPubMed
8.
Mann CD, Metcalfe MS, Leopardi LN, et al. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg. 2004;139:1168–72.CrossRefPubMed
9.
Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19:59–71.CrossRefPubMed
10.
Smith MD, McCall JL. Systematic review of tumour number and outcome after radical treatment of colorectal liver metastases. Br J Surg. 2009;96:1101–13.CrossRefPubMed
11.
Du L, Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008;14:6751–60.CrossRefPubMed
12.
Huang EH, Hynes MJ, Zhang T, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009;69:3382–9.CrossRefPubMedPubMedCentral
13.
Melin C, Perraud A, Akil H, et al. Cancer stem cell sorting from colorectal cancer cell lines by sedimentation field flow fractionation. Anal Chem. 2012;84:1549–56.CrossRefPubMed
14.
Vermeulen L, Todaro M, de Sousa Mello F, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA. 2008;105:13427–32.CrossRefPubMedPubMedCentral
15.
O’Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–10.CrossRefPubMed
16.
Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–5.CrossRefPubMed
17.
Toren A, Bielorai B, Jacob-Hirsch J, et al. CD133-positive hematopoietic stem cell “stemness” genes contain many genes mutated or abnormally expressed in leukemia. Stem Cells. 2005;23:1142–53.CrossRefPubMed
18.
Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51.CrossRefPubMed
19.
Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504–14.CrossRefPubMed
20.
Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313–23.CrossRefPubMed
21.
Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133 + cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67.CrossRefPubMedPubMedCentral
22.
Wang YK, Zhu YL, Qiu FM, et al. Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133 + primary colon cancer cells. Carcinogenesis. 2010;31:1376–80.CrossRefPubMed
23.
Hongo K, Tanaka J, Tsuno NH, et al. CD133(−) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the beta1-integrin signaling. J Surg Res. 2012;175:278–88.CrossRefPubMed
24.
25.
Chen S, Song X, Chen Z, et al. CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS One. 2013;8:e56380.CrossRefPubMedPubMedCentral
26.
Yamamoto S, Tanaka K, Takeda K, et al. Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy. Ann Surg Oncol. 2014;21:1853–61.CrossRefPubMed
27.
Hongo K, Kazama S, Sunami E, et al. Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer. Med Oncol. 2012;29:2849–57.CrossRefPubMedPubMedCentral
28.
Maeda S, Shinchi H, Kurahara H, et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer. 2008;98:1389–97.CrossRefPubMedPubMedCentral
29.
Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37:360–3.PubMed
30.
Lugli A, Iezzi G, Hostettler I, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer. 2010;103:382–90.CrossRefPubMedPubMedCentral
31.
Choi D, Lee HW, Hur KY, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol. 2009;15:2258–64.CrossRefPubMedPubMedCentral
32.
Garcia VM, Batlle JF, Casado E, et al. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy. Colorectal Dis. 2011;13:989–98.CrossRefPubMed
33.
Nagata T, Sakakura C, Komiyama S, et al. Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer. Anticancer Res. 2011;31:495–500.PubMed
34.
Zhou F, Mu YD, Liang J, et al. Expression and prognostic value of tumor stem cell markers ALDH1 and CD133 in colorectal carcinoma. Oncol Lett. 2014;7:507–12.PubMedPubMedCentral
35.
Gao W, Chen L, Ma Z, et al. Isolation and phenotypic characterization of colorectal cancer stem cells with organ-specific metastatic potential. Gastroenterology. 2013;145:636–46.e5.PubMed
36.
Lehwald N, Duhme C, Wildner M, et al. HGF and SDF-1-mediated mobilization of CD133 + BMSC for hepatic regeneration following extensive liver resection. Liver Int. 2014;34:89–101.CrossRefPubMed
Metadata
Title
CD133 Expression at the Metastatic Site Predicts Patients’ Outcome in Colorectal Cancer with Synchronous Liver Metastasis
Authors
Junko Kishikawa, MD
Shinsuke Kazama, MD, PhD
Koji Oba, PhD
Kiyoshi Hasegawa, MD, PhD
Hiroyuki Anzai, MD
Yuzo Harada, MD
Hiroyuki Abe, MD, PhD
Keisuke Matsusaka, MD, PhD
Kumiko Hongo, MD, PhD
Masaru Oba, MD, PhD
Koji Yasuda, MD, PhD
Kensuke Otani, MD, PhD
Takeshi Nishikawa, MD, PhD
Toshiaki Tanaka, MD, PhD
Junichiro Tanaka, MD, PhD
Tomomichi Kiyomatsu, MD, PhD
Keisuke Hata, MD, PhD
Kazushige Kawai, MD, PhD
Hiroaki Nozawa, MD, PhD
Hironori Yamaguchi, MD, PhD
Soichiro Ishihara, MD, PhD
Eiji Sunami, MD, PhD
Tetsuo Ushiku, MD, PhD
Joji Kitayama, MD, PhD
Masashi Fukayama, MD, PhD
Norihiro Kokudo, MD, PhD
Toshiaki Watanabe, MD, PhD
Publication date
01-06-2016
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 6/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5099-1

Other articles of this Issue 6/2016

Annals of Surgical Oncology 6/2016 Go to the issue

Pancreatic Tumors

Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2–≤4, pT3: >4 cm) is More Valid and Clinically Relevant

Gynecologic Oncology

Do Patients After Reexcision Due to Involved or Close Margins Have the Same Risk of Local Recurrence as Those After One-Step Breast-Conserving Surgery?

Thoracic Oncology

Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis

Bone and Soft Tissue Sarcomas

Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01)

Gastrointestinal Oncology

Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis

Colorectal Cancer

Comparison of Long-Term Outcomes Between Emergency Surgery and Bridge to Surgery for Malignant Obstruction in Right-Sided Colon Cancer: A Multicenter Retrospective Study